Cargando…

Real World Characteristics and Clinical Outcomes of HER2-Mutant Non–Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing

PURPOSE: This study was conducted to investigate the clinical characteristics of patients with advanced non–small cell lung cancer (NSCLC) harboring human epidermal growth factor receptor 2 (HER2) mutations and to evaluate response to standard treatment and HER2-targeted agents. MATERIALS AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahn, Beung-Chul, Han, Ye-Jeong, Kim, Hye Ryun, Hong, Min Hee, Cho, Byoung Chul, Lim, Sun Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101791/ https://www.ncbi.nlm.nih.gov/pubmed/36397236 http://dx.doi.org/10.4143/crt.2022.359

Ejemplares similares

Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
por: Ahn, Beung-Chul, et al.
Publicado: (2021)

Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
por: Hong, Min Hee, et al.
Publicado: (2019)

Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
por: Ahn, Beung-Chul, et al.
Publicado: (2019)

A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
por: Lee, Ji Hyun, et al.
Publicado: (2021)

Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Ahn, Beung-Chul, et al.
Publicado: (2021)

Predicting treatment outcomes using (18)F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy
por: Kim, Chang Gon, et al.
Publicado: (2022)

Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing
por: Chun, You Jin, et al.
Publicado: (2019)

Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
por: Lim, Sun Min, et al.
Publicado: (2016)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
por: Lee, Jiyun, et al.
Publicado: (2022)

Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma
por: Kim, Seok-Young, et al.
Publicado: (2019)

Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma
por: Lim, Sun Min, et al.
Publicado: (2019)

Clinical Application of Next-Generation Sequencing in Patients With Breast Cancer: Real-World Data
por: Suh, Koung Jin, et al.
Publicado: (2022)

The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
por: Sang, Yun Beom, et al.
Publicado: (2022)

Omalizumab Treatment in Patients With Cholinergic Urticaria: A Real-World Retrospective Study in Korea
por: Kim, Ji Hye, et al.
Publicado: (2020)

Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
por: Lim, Sun Min, et al.
Publicado: (2016)

Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer
por: Cho, Jae-Won, et al.
Publicado: (2020)

Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
por: Lim, Sun Min, et al.
Publicado: (2020)

Safety and Clinical Outcomes of Insulin Degludec in Korean Patients with Diabetes in Real-World Practices: A Prospective, Observational Study
por: Lee, Byung Wan, et al.
Publicado: (2023)

The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma
por: Park, Seong Yong, et al.
Publicado: (2020)

Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy
por: Sung, MinDong, et al.
Publicado: (2023)

Real‐world utility of next‐generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma
por: Kim, Jwa Hoon, et al.
Publicado: (2021)

Light-Weight Student LSTM for Real-Time Wildfire Smoke Detection
por: Jeong, Mira, et al.
Publicado: (2020)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

The Value of Next-Generation Sequencing for Treatment in Non-Small Cell Lung Cancer Patients: The Observational, Real-World Evidence in China
por: Zhang, Yan, et al.
Publicado: (2020)

Real World Comparison of Rivaroxaban and Warfarin in Korean Patients with Atrial Fibrillation: Propensity Matching Cohort Analysis
por: Jeong, Hyung Ki, et al.
Publicado: (2019)

Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution
por: Park, Hyung Soon, et al.
Publicado: (2016)

Mutant HER2 needs mutant HER3 to be an effective oncogene
por: Trenker, Raphael, et al.
Publicado: (2021)

Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea
por: Molife, Cliff, et al.
Publicado: (2022)

Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data
por: Kim, Tae-Hwan, et al.
Publicado: (2021)

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
por: Bae, Soong June, et al.
Publicado: (2021)

Driver’s Facial Expression Recognition in Real-Time for Safe Driving
por: Jeong, Mira, et al.
Publicado: (2018)

Development of microsatellite markers for the endangered Pedicularis ishidoyana (Orobanchaceae) using next-generation sequencing(1)
por: Cho, Won-Bum, et al.
Publicado: (2015)

Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models
por: Lim, Sun Min, et al.
Publicado: (2022)

Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
por: Lee, Yong-Pyo, et al.
Publicado: (2022)

Optimal dose and volume for postoperative radiotherapy in brain oligometastases from lung cancer: a retrospective study
por: Chung, Seung Yeun, et al.
Publicado: (2017)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy
por: Lee, Jii Bum, et al.
Publicado: (2022)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

Prognostic implications of PD-L1 expression in patients with angiosarcoma
por: Lee, Jii Bum, et al.
Publicado: (2021)

Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients
por: Hempel, Dirk, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ouggarjj2nin0vg049fcqqd9l0